Status:
RECRUITING
A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity
Lead Sponsor:
Innovent Biologics Technology Limited (Shanghai R&D Center)
Conditions:
Part A: Healthy Part B: Overweight or Obesity
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI303...
Eligibility Criteria
Inclusion
- Male or female aged 18-65 years (inclusive) at the time of informed consent.
- Participants must understand the procedures and methods of this study, be willing to complete the study in strict accordance with the clinical study protocol, and voluntarily sign the informed consent form.
Exclusion
- The investigator suspects that the participant may be allergic to any component of the study drug or GLP-1 receptor agonists, or have used GLP-1 receptor agonists within 3 months prior to screening.
- History of diabetes, or HbA1c ≥ 6.5% and fasting blood glucose \< 3.9 mmol/L or ≥ 7.0 mmol/Lat screening.
- Presence of any other abnormalities in vital signs and laboratory tests that are clinically significant as judged by the investigator at screening.
Key Trial Info
Start Date :
August 27 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2026
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT07160400
Start Date
August 27 2025
End Date
March 31 2026
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China, 200030